Alligator Bioscience Enters into License Agreement with Biotheus
The agreement gives Biotheus access to Alligator’s antibody, Alligator-Gold, for the creation of up to three bispecific molecules.
Alligator Bioscience, a Swedish research-based biotechnology company focused on antibody therapeutics for cancer, announced on Aug. 20, 2019 that it is entering into a license agreement with Biotheus, a privately held Chinese company based in Zhuhai, Guangdong, China. The agreement gives Biotheus rights in Greater China to Alligator’s antibody, Alligator-Gold, for the creation of up to three bispecific molecules.
Alligator will receive $0.5 million upon signing and another $0.5 million after six months of scientific-technical evaluation. The agreement gives Alligator eligibility to receive upfront, milestones, and option fees up to a total of $142 million, which includes upfront and development milestones amounting to $52 million, global option fees up to $90 million, royalties on future sales, and a share of sublicense revenue.
“This agreement is a great recognition of our antibody library and our proven expertise in generating high affinity antibodies against TNFR family members, and this collaboration with an up and coming Chinese biotech firm like Biotheus gives us an entrance to the fast advancing life science market in China,” said Per Norlén, CEO of Alligator, in a company press release.
Source: Alligator Bioscience
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
